# ASIS for Enbrel in Plaque Psoriasis

> **NCT02112097** · PHASE1,PHASE2 · UNKNOWN · sponsor: **ASIS Corporation** · enrollment: 60 (estimated)

## Conditions studied

- Plaque Psoriasis.

## Interventions

- **DRUG:** Gadolinium
- **DRUG:** Gadolinium
- **DRUG:** Gadolinium
- **DRUG:** Efficacy of Enbrel subcutaneously at Week 12
- **DRUG:** Efficacy of Enbrel subcutaneously at Week 24
- **DRUG:** Efficacy of Enbrel subcutaneously at Week 36
- **DRUG:** Efficacy of Enbrel subdermally at Week 12
- **DRUG:** Efficacy of Enbrel subdermally at Week 24
- **DRUG:** Efficacy of Enbrel subdermally at Week 36
- **DRUG:** PASI 75 n(%) subcutaneously at Week 12
- **DRUG:** PASI 75 n(%) subcutaneously at Week 24
- **DRUG:** PASI 75 n(%) subcutaneously at Week 36
- **DRUG:** PASI 75 n(%) subdermally at Week 12
- **DRUG:** PASI 75 n(%) subdermally at Week 24
- **DRUG:** PASI 75 n(%) subdermally at Week 36
- **DRUG:** Adverse Reactions of Enbrel subcutaneously
- **DRUG:** Adverse Reactions of Enbrel subdermally at Week 36
- **DRUG:** Gadolinium
- **DRUG:** Gadolinium
- **DRUG:** Gadolinium

## Key facts

- **NCT ID:** NCT02112097
- **Lead sponsor:** ASIS Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2016-06
- **Final completion:** 2017-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2015-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02112097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02112097, "ASIS for Enbrel in Plaque Psoriasis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02112097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*